Using engineered probiotics to block harmful toxins from C. difficile.
Neutralizing C. difficile toxicity with probiotics that secrete rationally-designed inhibitory peptides.
This study is testing a new treatment for Clostridioides difficile infections that uses specially designed probiotic yeast to help neutralize the harmful toxins causing your gut issues, offering a potentially better and gentler option than regular antibiotics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Carolina State University Raleigh NIH-funded |
| Lab location | 1 site (Raleigh, United States) |
| Project ID | NIH-11074980 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for Clostridioides difficile infections (CDI), which cause severe gastrointestinal issues. The approach involves engineering probiotic yeast to deliver specially designed peptides that neutralize the harmful toxins produced by C. difficile. By targeting these toxins directly, the treatment aims to restore balance in the gut microbiome and reduce inflammation. Patients may benefit from a more effective and less invasive alternative to traditional antibiotic therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing recurrent or severe C. difficile infections.
Not a fit: Patients who do not have C. difficile infections or those with other gastrointestinal disorders unrelated to this pathogen may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from C. difficile infections, potentially reducing the severity and duration of their symptoms.
How similar studies have performed: Previous research has shown promise in using biotherapeutics to combat C. difficile, but this specific approach using engineered probiotics is relatively novel.
Where this research is happening
Raleigh, United States
- North Carolina State University Raleigh — Raleigh, United States (Active)
Researchers
- Principal investigator: Crook, Nathan C. — North Carolina State University Raleigh
- Study coordinator: Crook, Nathan C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.